Scancell Hldgs Plc (SCLP) - Cash Flow Conversion Efficiency

Latest as of October 2025: 0.846x

Based on the latest financial reports, Scancell Hldgs Plc (SCLP) has a cash flow conversion efficiency ratio of 0.846x as of October 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-7.08 Million ≈ $-861.55 USD) by net assets (GBX-8.37 Million ≈ $-1.02K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Scancell Hldgs Plc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.

Scancell Hldgs Plc - Cash Flow Conversion Efficiency Trend (2009–2025)

This chart illustrates how Scancell Hldgs Plc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Scancell Hldgs Plc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Scancell Hldgs Plc ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
CDN Maverick Capital Corp.
F:338B
-0.120x
CVC Income & Growth Limited
LSE:CVCG
0.019x
Vendetta Mining Corp
V:VTT
-0.002x
Quebec Precious Metals Corporation
V:QPM
-4.369x
City Of London Investment Group
LSE:CLIG
0.070x
Autozi Internet Technology (Global) Ltd. Class A Ordinary Shares
NASDAQ:AZI
-0.029x
Invinity Energy Systems PLC
LSE:IES
-0.083x
Zynex Inc
NASDAQ:ZYXI
0.152x

Annual Cash Flow Conversion Efficiency for Scancell Hldgs Plc (2009–2025)

The table below shows the annual cash flow conversion efficiency of Scancell Hldgs Plc from 2009 to 2025. For the full company profile with market capitalisation and key ratios, see Scancell Hldgs Plc stock valuation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-04-30 GBX-3.83 Million
≈ $-466.61
GBX-6.11 Million
≈ $-742.92
1.592x -64.36%
2024-04-30 GBX-3.50 Million
≈ $-426.46
GBX-15.66 Million
≈ $-1.91K
4.468x +242.12%
2023-04-30 GBX-6.23 Million
≈ $-758.38
GBX-8.14 Million
≈ $-990.40
1.306x +426.11%
2022-04-30 GBX19.48 Million
≈ $2.37K
GBX-7.80 Million
≈ $-949.40
-0.400x +60.75%
2021-04-30 GBX7.65 Million
≈ $930.54
GBX-7.80 Million
≈ $-949.40
-1.020x -35.45%
2020-04-30 GBX9.34 Million
≈ $1.14K
GBX-7.03 Million
≈ $-855.71
-0.753x -0.21%
2019-04-30 GBX9.34 Million
≈ $1.14K
GBX-7.02 Million
≈ $-853.88
-0.752x -157.92%
2018-04-30 GBX13.94 Million
≈ $1.70K
GBX-4.06 Million
≈ $-494.32
-0.291x +50.77%
2017-04-30 GBX6.50 Million
≈ $790.78
GBX-3.85 Million
≈ $-468.13
-0.592x -153.79%
2016-04-30 GBX9.99 Million
≈ $1.22K
GBX-2.33 Million
≈ $-283.58
-0.233x +40.30%
2015-04-30 GBX6.75 Million
≈ $821.77
GBX-2.64 Million
≈ $-321.06
-0.391x -69.41%
2014-04-30 GBX9.08 Million
≈ $1.10K
GBX-2.09 Million
≈ $-254.70
-0.231x +41.23%
2013-04-30 GBX5.09 Million
≈ $619.57
GBX-2.00 Million
≈ $-243.14
-0.392x -418.26%
2012-04-30 GBX6.97 Million
≈ $848.21
GBX859.62K
≈ $104.59
0.123x +132.17%
2011-04-30 GBX4.64 Million
≈ $564.07
GBX-1.78 Million
≈ $-216.21
-0.383x -76.43%
2010-04-30 GBX6.05 Million
≈ $735.87
GBX-1.31 Million
≈ $-159.88
-0.217x -7.79%
2009-04-30 GBX5.25 Million
≈ $639.26
GBX-1.06 Million
≈ $-128.85
-0.202x --

About Scancell Hldgs Plc

LSE:SCLP UK Biotechnology
Market Cap
$2.62 Million
GBX21.53 Billion GBX
Market Cap Rank
#29641 Global
#622 in UK
Share Price
GBX20.75
Change (1 day)
+0.00%
52-Week Range
GBX8.54 - GBX26.50
All Time High
GBX27.50
About

Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer. It also develops Modi-1, an active peptide immunotherapy that is in phase I… Read more